Serum adiponectin in breast cancer
A meta-analysis

Li Gu, MD\textsuperscript{a,b}, Chang Cao, MD\textsuperscript{c}, Jing Fu, MD\textsuperscript{d}, Qian Li, MD\textsuperscript{e}, De-Hua Li, MD\textsuperscript{b,5}, Ming-Yao Chen, MD\textsuperscript{g}

Abstract

Background: Accumulating data have found that adiponectin is involved in development of breast cancer (BC). However, these results were inconsistent.

Method: A systematic search in PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure databases were conducted up to October 1, 2017. The standardized mean difference (SMD) with 95% confidence interval was applied to pool the effect size.

Results: Finally, 31 eligible studies were included in this meta-analysis. The overall results indicated that serum adiponectin levels in BC cases were significantly lower than the controls (SMD = −0.33, \(P < 0.0001\)). As for the subgroup analysis of menstrual status, serum adiponectin levels were significantly lower in pre- and postmenopausal BC cases. Moreover, the subgroup analysis by ethnicity in pre- and postmenopausal group indicated an inverse association between adiponectin levels and BC risk in Asian population, but not in Caucasian population.

Conclusion: The present meta-analysis suggests that low serum adiponectin concentration may be associated with an increased BC risk in premenopausal and postmenopausal women, especially among Asians. Adiponectin may serve as a biomarker of BC risk and help to identify subjects at high risk for BC development.

Abbreviations: BC = breast cancer, CI = confidence interval, ELISA = enzyme-linked immunosorbent assay, FEM = fixed-effects model, LN = lymph node invasion, NOS = Newcastle-Ottawa scale, REM = random-effects model, SMD = standardized mean difference, VEGF = vascular endothelial growth factor.

Keywords: adiponectin, breast cancer, meta-analysis

1. Introduction

Breast cancer (BC) is the most common cancer diagnosed and the leading cause of cancer-related death in women worldwide.\textsuperscript{[1,11]} It was estimated that there were 1.67 million new BC cases and 521,900 deaths due to BC globally based on the data from International Agency for Research on Cancer in 2012.\textsuperscript{[31]} Although great advancements in cancer diagnosis and treatment recently, the 5-year relative survival of BC is still less than 20%.\textsuperscript{[11]} Thus, it is urgent to identify new prognostic biomarkers involved in BC, which help to make early diagnosis, monitor tumor progression, and optimize medical management. Recent evidence has indicated that obesity was a well-recognized risk factor for BC development and recurrence, which is also linked to late-stage disease and poor prognosis.\textsuperscript{[1,4]} The precise mechanism linking obesity and BC risk remains unclear, but it has been noted that adipose tissue can produce a group of polypeptide growth factors and cytokines including adiponectin and leptin, which may underlie such association and serve as potential biomarkers and therapeutic targets for the management of this aggressive disease.\textsuperscript{[3,17]}

Adiponectin, a 244-amino acid polypeptide protein, is encoded on chromosome 3q27.\textsuperscript{[27]} It is an insulin-sensitizing hormone secreted mainly by adipocytes of white adipose tissue, which play pivotal roles in regulation of energy homeostasis, inflammation, insulin sensitivity, and cell proliferation.\textsuperscript{[27]} The published studies have suggested that the low serum adiponectin concentration was associated with hyperinsulinemia and increased vascular endothelial growth factor (VEGF) and insulin-like growth factor levels, which have been demonstrated to increase the risk of obesity-related malignancies, including BC.\textsuperscript{[10,11]} However, some studies indicated no significant association between serum...
Table 1
Characteristics of included studies in this meta-analysis.

| Author              | Year | Ethnicity | Country          | Age     | Sample size | Control source | Cancer type | Treatment status | Stage | Overall |
|---------------------|------|-----------|------------------|---------|-------------|----------------|-------------|------------------|-------|---------|
| Ozmen et al         | 2017 | Caucasian | Turkish          | 51±4/7   | 88          | Population     | BC          | N                | 0/39/19/0 |         |
| Georgiou et al      | 2017 | Caucasian | Greece           | 57±11/6   | 209         | Hospital       | IDC/DCIS    | N                | NR    |         |
| Cristostomo et al   | 2017 | Caucasian | Portugal         | 39±8/28-40| 154         | Hospital       | BC          | N                | NR    |         |
| Minatoya et al      | 2015 | Asian     | Japan            | 32±7/41-70| 139         | Hospital       | BC          | Y                | NR    |         |
| Guo et al           | 2015 | Asian     | China            | 47±4/47±9 | 2434        | Hospital       | BC          | N                | NR    |         |
| Gunter et al        | 2015 | Mix       | America          | 59±57/57-69| 1696        | Population     | BC          | N                | NR    |         |
| Assali et al        | 2015 | Asian     | Saudi            | 50±1/36±2 | 150         | NR             | BC          | N                | NR    |         |
| Ahmed et al         | 2015 | Asian     | Pakistan         | 40±1/45±1 | 250         | Hospital       | BC          | N                | NR    |         |
| Touvier et al       | 2014 | Caucasian | France           | 49±5/61±6 | 1242        | Population     | BC          | N                | NR    |         |
| Santillan-Benitez et al | 2014 | Asian     | Mexico           | 40±50/40-50| 88          | Hospital       | BC          | N                | 4/9/11/7 |         |
| Olfbernding et al   | 2013 | Mix       | America          | 67±768±7  | 1412        | Population     | BC          | N                | NR    |         |
| Gross et al         | 2013 | Caucasian | America          | 62±9/63±9 | 544         | Population     | BC          | N                | NR    |         |
| Dalamagka et al     | 2013 | Caucasian | Athens           | 62±6/62±9 | 204         | Hospital       | BC          | N                | NR    |         |
| Akolai et al        | 2013 | Asian     | Saudi            | 43±4/46±11| 109         | NR             | BC          | N                | NR    |         |
| Wang et al          | 2013 | Asian     | China            | 48±69/47-69| 152         | Hospital       | Breast carcinoma| N       | 30/28/19 |         |
| Zhang et al         | 2012 | Asian     | China            | 25±70/25-70| 86          | Population     | BC          | NR               | NR    |         |
| Galcik et al        | 2012 | Caucasian | Turkish          | 51±12/52±10| 123         | Hospital       | BC          | Y                | 2/25/26 |         |
| Al Awadi et al      | 2012 | Asian     | Kuwait           | 50±12/51±12| 221         | Population     | BC          | N                | NR    |         |
| Al Khaldi et al     | 2011 | Asian     | Kuwait           | 49±2/60±5 | 120         | Hospital       | BC          | NR               | NR    |         |
| Fan et al           | 2010 | Asian     | China            | 38±77/17  | 140         | NR             | BC          | N                | 15/48/27 |         |
| Shahar et al        | 2010 | Asian     | Malaysia         | 47±6/46±6 | 208         | Population     | BC          | N                | NR    |         |
| Hanci et al         | 2010 | Caucasian | German           | 59±14/19±1| 200         | NR             | BC          | Y                | NR    |         |
| Cuss et al          | 2009 | Caucasian | Australia        | 50±59/60-59| 1122        | Population     | BC          | N                | 263/256/21/14 |         |
| Tovroger et al (1)  | 2007 | Caucasian | America          | 57±5/58-7 | 2741        | NR             | BC          | N                | NR    |         |
| Tovroger et al (2)  | 2007 | Caucasian | America          | 45±4/45-4 | 932         | NR             | BC          | N                | NR    |         |
| Kortner et al       | 2007 | Caucasian | German           | 38±82/30-82| 150         | Population     | Breast carcinoma| N       | 19/32/14/9 |         |
| Kang et al          | 2007 | Asian     | Korea            | 47±9/48±6 | 84          | Hospital       | BC          | NR               | NR    |         |
| Hou et al           | 2007 | Asian     | China            | 19±7/36±63 | 130         | Hospital       | Breast carcinoma| N       | 13/43/24 |         |
| Chen et al          | 2006 | Asian     | Taiwan           | 50±1/40±2 | 200         | Hospital       | BC          | N                | 37/39/24 |         |
| Mantzoros et al     | 2004 | Caucasian | America          | 45±7/5/45-5| 341         | Hospital       | BC          | NR               | NR    |         |
| Miyoshi et al       | 2003 | Asian     | Japan            | 54±1/53±1 | 202         | Population     | BC          | N                | NR    |         |

BC = breast cancer, DCIS = in-situ ductal carcinoma, IDC = infiltrating duct carcinoma, ILC = invasive lobular carcinoma, NR = not report, N, non-treatment.

adiponectin levels and risk of BC. In addition, several studies have demonstrated significant low serum concentration of adiponectin in postmenopausal BC cases, while other studies reported controversial findings in premenopausal women with BC. This profile may be correlated with menstrual status and the observed association between adiponectin and BC in these studies was inconsistent. Up to now, several meta-analyses based on different strategies tried to investigate the relationship between adiponectin levels and BC risk. Unfortunately, the sample size in these studies was not large enough to reveal a reliable relationship. Furthermore, growing evidence suggests that different populations living in different areas might have different genetic backgrounds, different homeostasis model assessment (HOMA) indexes, and different sex-hormone-binding globulin and high-density lipoprotein cholesterol levels, which were associated with adiponectin concentration and had an effect on the results. In addition, different populations may have different living and diet habits, which may also substantially affect serum adiponectin levels. Thus, the ethnicity may be an important factor affecting the results. However, no such subgroup analyses were conducted based on ethnicity.

Moreover, obviously high heterogeneity was identified, but no meta-regression analysis was performed to investigate confounding factors. The eligible studies in these meta-analyses have different quality scores and the low-quality study of the overall results, which may result in bias. Henceforth, some new studies were performed to investigate the link between adiponectin and BC on multiple ethnic populations. However, the results remain inconclusive. Therefore, the data need to be updated, and more reliable association of serum adiponectin levels with the risk of BC is warranted. Due to the critical role of adiponectin in the pathogenesis of BC and the inconsistency of these studies, an updated meta-analysis was conducted to assess the association between serum adiponectin concentration and BC risk by precise results.

2. Materials and methods

2.1. Literature search

The preferred reporting items for systematic reviews and meta-analyses protocol was prospectively conducted. Ethical approval was unnecessary in this study because it was a meta-analysis analyzing existing articles and did not need handle individual patient data. Two independent reviewers conducted a systematic literature search in the PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure databases to identify relevant studies from inception to October 1, 2017. The search terms were as follows: “adiponectin” AND “breast neoplasms” or “breast neoplasm” or “breast tumor” or “breast tumors” or “breast cancer” or “human mammary neoplasm” or “human mammary neoplasm” or “human mammary carcinoma.” No
publication approval was not necessary, because available data were collected from the previous published studies.

### 2.2. Inclusion and exclusion criteria

The inclusion criteria were as follows: a study designed as case-control study; a study evaluating the association between serum/plasma adiponectin levels and BC; sufficient data available for calculating standardized mean difference (SMD) with 95% confidence interval (CI); the participants of the study should be human; all patients were pathologically diagnosed as BC.

Exclusion criteria: duplicative or overlapping publications; a study with incomplete data; abstracts, conferences, letters, or case reports. Only the study with the largest number of subjects was included when multiple studies were based on the same case series. Two independent investigators reviewed the references list of previous meta-analyses for potentially relevant publications.

### 2.3. Data extraction

The information of included studies was collected independently by 2 investigators with use of a predesigned data extraction form. Items were collected as follows: first author, publication date, country, age, ethnicity, sample size, control source, sample size, cancer type, serum adiponectin levels (mean and standard deviation), test method, menstrual status, lymph node invasion (LN), and treatment status. The third author would further recheck these publications if there was any discrepancy. The information is shown in Tables 1 and 2.

### 2.4. Quality assessment

The quality of each eligible study was evaluated according to Newcastle-Ottawa scale. A "**" rating system was used to assess quality based on 3 broad perspectives, including selection, comparability, exposure in the primary study.[35] The total scores ranged 0 to 9. A study with scores of 7 to 9 points was considered as a high-quality study (Table 2).

### 2.5. Statistical analysis

All collected data were calculated as the SMD with 95% CI to evaluate the association between serum adiponectin levels and BC. Heterogeneity was examined with use of Chi-squared-based Q test and I² statistics and P value < 0.10 was considered
statistically significant. The pooled SMD would be computed by the fixed-effects model (FEM) if there was no or low heterogeneity ($I^2 > 50\%$ and $P < 0.10$). If not, the random-effects model (REM) was applied. Subgroup analyses based on ethnicity (Asian and Caucasian), control source (hospital-based [HB] and population-based [PB] population), menstrual status, and study quality-specific effects were conducted to investigate the potential origin of heterogeneity. Moreover, sensitivity analyses and multivariate meta-regression analysis were also performed to evaluate the stability of the results.

Potential publication bias was tested by Egger’s linear regression and Begg’s test and $P < 0.05$ indicated statistically significant publication bias. Visual inspection of asymmetry in funnel plots was conducted to detect publication bias. All data analyses were performed with STATA 12.0 software (Stata Corp LP, College Station, TX).

**Table 3**

The levels of serum adiponectin in pre- and postmenopausal breast cancer cases and controls.

| Author         | Year | Menstrual status | Cases Mean SD N | Cases Mean SD N | Unit   |
|----------------|------|------------------|-----------------|-----------------|--------|
| Georgiou et al | 2017 | Pre              | 10.82 3.6 44    | 11.39 4.8 17    | μg/mL  |
| Georgiou et al | 2017 | Post             | 13.19 9.37 113  | 13.35 4.94 35   | μg/mL  |
| Minatoya et al | 2015 | Pre              | 4.6 2.3 22      | 7.1 5.2 31      | μg/mL  |
| Minatoya et al | 2015 | Post             | 5.2 3.6 41      | 8.8 5.9 45      | μg/mL  |
| Guo et al      | 2015 | Pre              | 6.24 3.46 745   | 6.44 3.57 785   | μg/mL  |
| Guo et al      | 2015 | Post             | 6.58 3.74 396   | 6.95 4.08 339   | μg/mL  |
| Gunter et al   | 2015 | Post             | 28.59 14.79 875 | 29.32 14.39 821 | ng/mL  |
| Assiri et al   | 2015 | Pre              | 9.92 0.62 44    | 10.86 1.67 27   | ng/mL  |
| Assiri et al   | 2015 | Post             | 6.74 1.92 38    | 11.01 1.58 41   | ng/mL  |
| Ahmed et al    | 2015 | Pre              | 6.63 1.45 175   | 10.17 5.29 175  | μg/mL  |
| Gross et al    | 2013 | Post             | 7.99 3.83 272   | 8.7 4.04 272    | μg/mL  |
| Dalamaga et al | 2013 | Post             | 16.9 9.8 102    | 19.8 10.1 102   | μg/mL  |
| Gulcelik et al | 2012 | Pre              | 8.44 2.02 41    | 13.7 3.12 20    | μg/mL  |
| Gulcelik et al | 2012 | Post             | 8.72 2.17 42    | 14.13 3.4 20    | μg/mL  |
| Fan et al      | 2010 | Pre              | 9.31 2.34 48    | 10.06 2.86 26   | μg/mL  |
| Fan et al      | 2010 | Post             | 7.74 3.33 42    | 10.43 2.81 24   | μg/mL  |
| Hancke et al   | 2010 | Pre              | 15.78 6 40      | 17.14 6 25      | μg/mL  |
| Hancke et al   | 2010 | Post             | 19.45 7.63 119  | 18.77 6.8 16    | μg/mL  |
| Cust et al     | 2009 | Post             | 6.9 4.15 561    | 6.6 4.81 561    | μg/mL  |
| Hou et al      | 2007 | Pre              | 9.31 2.34 43    | 10.06 2.86 26   | μg/mL  |
| Hou et al      | 2007 | Post             | 7.74 3.33 37    | 10.43 2.81 24   | μg/mL  |
| Mantzoros et al| 2004 | Pre              | 14.5 7.8 49     | 13 7.1 44       | μg/mL  |
| Mantzoros et al| 2004 | Post             | 17.6 10.6 125   | 19 11.1 123     | μg/mL  |

Post = postmenopausal women, Pre, premenopausal women.
Table 4
The pooled and subgroup results of the serum adiponectin levels in breast cancer compared with controls.

| Indication             | N  | Cases | Control | SMD | 95% CI         | P     | F (%) | Model   |
|------------------------|----|-------|---------|-----|----------------|-------|-------|---------|
| Overall                | 31 | 7388  | 8491    | −0.33 | −0.48−0.18    | <0.0001 | 94.4 | Random |
| Ethnicity              |    |       |         |      |                |       |       |         |
| Asian                  | 15 | 2355  | 2278    | −0.61 | −0.96−0.25    | 0.001 | 96.1 | Random |
| Caucasian              | 14 | 3452  | 4686    | −0.12 | −0.27−0.05    | 0.168 | 89.7 | Random |
| Mix                    | 2  | 1581  | 1527    | −0.09 | −0.19−0.001   | 0.047 | 44.8 | Fixed  |
| Method                 |    |       |         |      |                |       |       |         |
| ELISA                  | 21 | 3764  | 3400    | −0.41 | −0.64−0.17    | 0.001 | 95   | Random |
| RIA                    | 7  | 2640  | 4124    | −0.11 | −0.30−0.09    | 0.268 | 91.7 | Random |
| Control source         |    |       |         |      |                |       |       |         |
| Population             | 11 | 3123  | 3848    | −0.41 | −0.65−0.17    | 0.001 | 95.1 | Random |
| Hospital               | 14 | 3123  | 2235    | −0.31 | −0.53−0.09    | 0.006 | 94.1 | Random |
| Treatment status       |    |       |         |      |                |       |       |         |
| N                      | 21 | 6335  | 7586    | −0.25 | −0.38−0.11    | <0.0001 | 92.2 | Random |
| NR                     | 7  | 748   | 748     | −0.49 | −1.14−0.16    | 0.137 | 96.9 | Random |
| Menstrual status       |    |       |         |      |                |       |       |         |
| Premenstrual           |    |       |         |      |                |       |       |         |
| Overall                | 10 | 1251  | 1176    | −0.50 | −0.85−0.15    | 0.005 | 90.3 | Random |
| Ethnicity              |    |       |         |      |                |       |       |         |
| Asian                  | 6  | 1077  | 1070    | −0.49 | −0.90−0.08    | 0.020 | 91.0 | Random |
| Caucasian              | 4  | 174   | 106     | −0.56 | −1.48−0.35    | 0.229 | 91.8 | Random |
| Postmenstrual          |    |       |         |      |                |       |       |         |
| Overall                | 13 | 2763  | 2423    | −0.46 | −0.68−0.25    | <0.0001 | 90.9 | Random |
| Ethnicity              |    |       |         |      |                |       |       |         |
| Asian                  | 5  | 544   | 473     | −0.97 | −1.72−0.22    | 0.011 | 94.3 | Random |
| Caucasian              | 7  | 1344  | 1129    | −0.26 | −0.53−0.01    | 0.056 | 87.0 | Random |
| Quality score          |    |       |         |      |                |       |       |         |
| High quality (≥7)      | 23 | 5416  | 5842    | −0.24 | −0.39−0.09    | 0.002 | 92.5 | Random |
| Low quality (<7)       | 8  | 1972  | 2649    | −0.68 | −1.14−0.22    | 0.004 | 97.1 | Random |
| High-quality group     |    |       |         |      |                |       |       |         |
| Ethnicity              |    |       |         |      |                |       |       |         |
| Asian                  | 9  | 834   | 770     | −0.46 | −0.90−0.02    | 0.041 | 93.5 | Random |
| Caucasian              | 11 | 3001  | 3545    | −0.15 | −0.32−0.04    | 0.115 | 89.6 | Random |
| Menstrual status       |    |       |         |      |                |       |       |         |
| Premenstrual           | 7  | 291   | 191     | −0.56 | −1.06−0.06    | 0.028 | 85   | Random |
| Postmenstrual          | 11 | 2248  | 2068    | −0.57 | −0.89−0.31    | <0.0001 | 92.4 | Random |
| Method                 |    |       |         |      |                |       |       |         |
| ELISA                  | 16 | 2166  | 1921    | −0.27 | −0.53−0.002   | 0.048 | 93.1 | Random |
| RIA                    | 5  | 2312  | 3024    | −0.13 | −0.33−0.08    | 0.232 | 98.9 | Random |
| Control source         |    |       |         |      |                |       |       |         |
| Population             | 8  | 2687  | 2671    | −0.15 | −0.28−0.02    | 0.022 | 75.1 | Random |
| Hospital               | 11 | 1048  | 830     | −0.58 | −0.91−0.24    | 0.001 | 91.7 | Random |
| Treatment status       |    |       |         |      |                |       |       |         |
| N                      | 16 | 4619  | 5074    | −0.20 | −0.34−0.06    | 0.006 | 89.6 | Random |
| NR                     | 4  | 651   | 652     | 0.06  | −0.41−0.53    | 0.80  | 93.6 | Random |
| BMI                    |    |       |         |      |                |       |       |         |
| <25                    | 4  | 846   | 881     | −0.25 | −0.40−0.00    | 0.002 | 99.2 | Random |
| >25                    | 2  | 623   | 598     | −0.02 | −0.23−0.19    | 0.888 | 33   | Fixed  |
| LN                     | 3  | 149   | 113     | −0.86 | −1.88−0.16    | 0.098 | 93.3 | Random |

**BMI** = body mass index, **CI** = confidence interval, **ELISA** = enzyme-linked immunosorbent assay, **N** = non-treatment, **NR** = not report, **RIA** = radioimmunoassay, **SMD** = standardized mean difference.

3. Results

3.1. Search results and study characteristics

As showed in Fig. 1, 774 articles were identified with our search strategy. A total of 707 studies were excluded after removing duplications and scanning titles and abstracts. A total of 37 articles were removed due to various reasons by further and full-screening. In addition, the publications by Tworoger et al.\(^\text{[34]}\) investigated the association of serum adiponectin levels with BC in 2 individual cohorts. Therefore, a total of 30 articles (31 case-control studies) meeting inclusion-exclusion criteria were eligible in this meta-analysis, which contained 15,879 subjects (7388 cases and 8491 controls) (Fig. 1).\(^\text{[12,13,16,17,22,23,27–34,36–31]}\)

Of the 31 included studies, 15 studies (4633 subjects) reported on Asians and 14 studies (8138 subjects) on Caucasians. Moreover, 11 studies employed PB control, while 14 studies applied HB control. As for measurement method, 21 studies were conducted with use of enzyme-linked immunosorbent assay (ELISA) and 7 studies with use of radioimmunoassay. For menstrual status, 10 studies included premenstrual women with BC, while 13 studies with postmenstrual women with BC. In addition, the estimated quality of each included study ranged
from 6 to 8 points. The main characteristics of included studies were presented in Tables 1–3.

3.2. Overall meta-analysis

As showed in Table 4, the results using the REM indicated that serum adiponectin levels in BC cases were signiﬁcantly lower than controls (SMD = −0.33, 95% CI = −0.48 to −0.18, P < 0.0001). However, a nonignorable heterogeneity was observed among studies (I² = 94.4%). Therefore, subgroup analyses of different speciﬁc effects were performed to investigate the origin of signiﬁcant heterogeneity.

3.3. Subgroup meta-analysis

In the subgroup analysis of ethnicity, lower serum adiponectin levels were detected in patients with BC in Asian population (SMD = −0.61, 95% CI = −0.96 to −0.25, P = 0.001), while no signiﬁcant difference between serum adiponectin levels, and BC was identiﬁed in Caucasian population (Fig. 2). As for stratiﬁcation by measurement method, serum adiponectin levels were signiﬁcantly lower in cases with BC in ELISA group (SMD = −0.41, 95% CI = −0.67 to −0.17, P = 0.001) (Fig. 3). However, there was no signiﬁcant association in radioimmunoassy group. We further conducted subgroup analysis by control source, and the results showed that signiﬁcantly lower serum adiponectin concentration was observed in PB group and HB group. Moreover, the subgroup analysis of treatment status indicated lower serum adiponectin concentration in nontreatment group (Table 4).

As for the subgroup analysis of menstrual status, the results demonstrated that serum adiponectin levels were signiﬁcantly lower in pre- and postmenopausal BC cases independently when compared with healthy controls (Fig. 4). We further conducted subgroup analysis by ethnicity; signiﬁcantly lower serum adiponectin concentration was identiﬁed in premenopausal BC patients for Asian population (SMD = −0.49, 95% CI = −0.90 to −0.08, P = 0.02). However, no signiﬁcant association was observed in Caucasian population (SMD = −0.56, 95% CI = −1.48 to 0.35, P = 0.229) (Table 4). Similarly, signiﬁcantly lower serum adiponectin concentration was identiﬁed in postmenopausal BC cases for Asian population (SMD = −0.97, 95% CI = −1.72 to −0.22, P = 0.011), but not for Caucasian population (SMD = −0.26, 95% CI = −0.53 to 0.01, P = 0.036) (Table 4).

The serum adiponectin concentration of the cases was signiﬁcantly lower in low- and high-quality group when compared with the controls (Fig. 5). As for the high-quality group, signiﬁcantly lower adiponectin concentration was seen in BC cases for Asian population, but not in Caucasian population (Fig. 6). Similarly, such signiﬁcant association was also identified
between serum adiponectin levels and BC in pre- and postmenopausal women. In addition, the subgroup analyses by measurement method, control source, and treatment status in the high-quality group indicated similar results (Table 4).

### 3.4. Association of serum adiponectin levels and clinicopathological features in BC

In the subgroup analysis of body mass index (BMI), the results indicated that serum adiponectin concentration was lower in BMI < 25 group. However, there was no association between serum adiponectin levels and BC in BMI > 25 group (Table 4). In addition, no significant difference was identified in serum adiponectin levels in BC cases with LN and without LN (SMD = −0.86, 95% CI = −1.88 to 0.16, P = 0.098) (Fig. 7).

### 3.5. Sensitivity analysis and meta-regression analysis

Although stringent protocols were applied in this meta-analysis, some of studies may affect the results of pooled analysis. Thus, sensitivity analyses were conducted to evaluate the stability of these results. First, sensitivity analysis was conducted by sequentially excluding each study to evaluate the effect of any individual study on the obtained conclusions. Moreover, the corresponding pooled SMDs were not significantly altered. Second, the REM was compared with the FEM, and the conclusions were not materially changed, which suggested the stability of our meta-analysis.

A multivariate meta-regression analysis was conducted to assess the potential confounding factors. The results indicated that the publish year, publish language, control source, and study quality as confounding factors did not substantially affect heterogeneity (adjusted P value is 0.099, 0.832, 0.332, and 0.486, respectively).

### 3.6. Publication bias

Publication bias was evaluated by the Begg’s funnel plot and Egger’s regression intercept tests. Egger’s test indicated that no significant publication bias was identified (data not shown). Moreover, the shape of the Begg’s funnel plot presented basically symmetric distribution (Fig. 8).

### 4. Discussion

BC is the most common malignancy among women worldwide. Although the targeted therapy of BC makes great progress, the amount of cancer-related deaths is still large due to ineffective treatment, the large population with advanced-stage BC at diagnosis, and poor prognosis of advanced BC. Thus, it is crucial to identify new specific biomarkers and therapeutic targets for BC to make early diagnosis and monitor tumor progression. Many studies have indicated the pivotal roles played by...
adiponectin in BC development, progression, and recurrence.\textsuperscript{52–55} However, these results remain inconsistent. Thus, a meta-analysis was conducted to determine the value of serum adiponectin levels in BC.

In the current meta-analysis, there were 31 studies investigating the association between serum adiponectin levels and BC risk. The overall results suggested significantly decreased serum adiponectin levels in the patients with BC compared with the controls. However, we must treat these results cautiously when referring to these findings due to a nonignorable heterogeneity, which may be contributed to the following variability: different populations (Caucasian and Asian populations) with different environments might have different genetic backgrounds and demographic characteristics; the results from the PB controls can represent the exposure situation of overall population; the patients in these studies has different tumor stages, size, molecular subtypes, lymph node metastasis status, and types of BC; different analytic methods were applied to measure the concentrations of serum adiponectin; the quality of these included studies was different; these BC cases had different menstrual status; different treatment statuses were identified in patients with BC; the included participants had different demographic characteristics and clinicopathological features. The abovementioned study features may have a substantial effect on the results.

First, a multivariate meta-regression analysis was conducted to evaluate confounding factors, and the results suggested that no significant differences among all the analyzed factors (the publish year, publish language, control source, and study quality) were identified. Furthermore, sensitivity analyses were conducted by sequentially excluding individual study and the corresponding pooled SMDs were similar, which indicated the stability of this study. Moreover, the summary estimates were calculated with REM to be more conservative, and the similar results were obtained. Therefore, we further evaluated the influence of several study features including ethnicity, control source, study quality, menstrual status, treatment status, and clinicopathological features of BC on between-study heterogeneity through subgroup analyses.

When subgroup analysis was restricted to menstrual status, our results revealed an inverse association in both premenopausal and postmenopausal women. When subgroup analysis by menstrual status was conducted in high-quality study group, the similar result was obtained. In addition, the result was consistent with previous study by Macis et al, which compared “highest” and “lowest” serum adiponectin concentration and reported an indication of a weak inverse relationship in postmenopausal women. Nevertheless, the association between adiponectin and premenopausal BC risk was just in the same direction, but not significant due to limited sample size analyzed.\textsuperscript{20} Interestingly, Ye et al\textsuperscript{19} included 8 studies to investigated the association between circulating adiponectin levels and BC. The pooled data indicated no association of adiponectin levels with risk of BC in premenopausal women. Moreover, Liu et al\textsuperscript{21} reported that there was no significant

\textbf{Figure 4.} Forest plot of breast cancer risk associated with serum adiponectin levels for the subgroup analysis by menstrual status (premenopausal and postmenopausal).
increased BC risk when comparing “highest” and “lowest” serum adiponectin levels. In addition, there was significantly high adiponectin levels in postmenopausal BC women, but not in premenopausal women with BC. In addition, Gui et al[18] demonstrated that there was no significant difference in premenopausal and postmenopausal BC women. Surprisingly, our results were contrary to the results of the 3 previous meta-analyses.[18,19,21] The result can be explained by the following reasons: we included larger sample size (31 case-control studies) regarding the relationship between serum adiponectin concentration and BC risk, which may be closer to the real value; the study by Ye et al[19] reported estimates that was not adjusted for confounders. Moreover, the study by Liu et al[21] were conducted with odds ratios calculated with different adjustment, which could bias the results and lead to an exaggerated effect size; the sensitivity analysis was performed by 2 different methods, and the corresponding pooled SMDs were similar; a multivariate meta-regression analysis was conducted to assess the potential confounding factors. Therefore, our results were more stable and credible; no subgroup analysis by menstrual status was conducted in the high-quality group to confirm the stability of the overall results, which may result in bias.

The above-mentioned meta-analyses did not conduct subgroup analysis by ethnicity.[19-21] In our study, the subgroup analysis by ethnicity in premenopausal and postmenopausal group indicated that the patients with BC showed significantly lower adiponectin levels than the healthy controls for Asian population, but not for Caucasian population. This discrepancy between Caucasians and Asians could be attributed to the genetic background, nongenetic risk factors, and different environments and life styles. Growing evidence suggests that different populations living in different areas might have different genetic backgrounds, different HOMA indexes, and different sex-hormone-binding globulin and high-density lipoprotein cholesterol levels, which is associated with adiponectin concentration and affect the results. In addition, different living and diet habits may also have a substantial effect on serum adiponectin levels. A low-calorie diet, regularly physical exercise, daily intake of fish, and medical interventions for weight loss may induced an increase in adiponectin levels.[26,56] Moreover, some pharmacological interventions, such as antihypertensive and anti-inflammatory, may also affect the secretion of adiponectin in adipose tissue.[56] In addition, in the subgroup analyses of treatment status, serum adiponectin in BC cases were found significantly lower in nontreatment group.

In the subgroup analysis of BMI and lymph node metastasis status, the results indicated a direction of an inverse association between serum adiponectin levels and BC in BMI > 25 group or in LN+ group. However, such relationship was not significant because of the relatively small numbers of studies (2 studies in BMI > 25 group and 3 in lymph node metastasis status group),
which reduce the power to detect such small difference and to reveal a reliable relationship. The clinicopathological features of BC were varied by tumor stage or grade, size, and molecular subtypes, but no subgroup analyses were conducted due to insufficient data to calculate the pooled SMDs. Nevertheless, some studies have demonstrated that there was a significant association between lower adiponectin levels and increased risk of BC with high tumor grade, or stage.\textsuperscript{[40,48]}

**Figure 6.** Forest plot of breast cancer risk associated with serum adiponectin levels for the subgroup analysis by ethnicity in high-quality study group (Caucasian and Asian).

**Figure 7.** Comparison of differences of the serum adiponectin concentration in breast cancer cases with or without lymph node invasion.
Although the mechanism remains unclear, there were several investigations with various propositions of molecular mechanisms, by which elevated serum adiponectin levels played a protective role in reducing the risk of BC development. These included decreased serum insulin levels and insulin resistance resulting in proliferation decrease of BC cells, downregulation of the expression of VEGF, decrease of estrogen levels, and the enhancement of cell differentiation.[8,9,22] In addition, the main functions of adiponectin in our body are its regulation of insulin sensitivity, inflammation, cell proliferation, energy homeostasis, and vascular reactivity, which serves as a key factor for molecular study and a therapeutic target for various human cancers, such as cervical cancer, ovarian cancer, and endometrial cancer.[2,57–60] Studies reported that serum adiponectin concentration affected the pathogenesis of cervical cancers by an inverse association with obesity, which may play an important role in inhibiting proliferation and activating apoptosis.[58] Moreover, low adiponectin levels increase the risk of developing ovarian cancer and ovarian hormones may affect the regulation of adiponectin receptor expression. In addition, high adiponectin levels are involved in a decreased risk of developing endometrial cancer through the insulin resistance and hypothyroidism that cause obesity.[19,20]

We note several potential limitations in this study. First, further analyses were not conducted to detect other aggressive clinicopathological features (tumor stages and histological grade) and different types of BC (estrogen receptor/progesterone receptor, human epidermal growth factor receptor 2- and Triple negative) due to insufficient original data. Second, the included studies were observational studies, which may have not been completely controlled for confounders. Despite these limitations, we created a strict protocol and conducted study selection and data identification to reduce potential bias through the whole process. Thus, the objectivity and reliability of the results are guaranteed.

In summary, this study indicated an intriguing association between low serum adiponectin levels and increased risk of BC. Further investigation is needed to explore a threshold of adiponectin which could have a protective effect against BC. Moreover, adiponectin may serve as a biomarker of BC risk and help to identify subjects at high risk for BC development. More rigorous and uniform case–control is necessary to confirm these results.

**Author contributions**

Formal analysis: Li Gu, Jing Fu, Chang Cao. Methodology: Li Gu, Jing Fu, Chang Cao, Qian Li, De-Hua Li.

**References**

[1] Keramattinia A, Mousavi-Jarrahi SH, Hineh M, et al. Trends in incidence of breast cancer among women under 40 in Asia. Asian Pac J Cancer Prev 2014;15:1387–90.
[2] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
[3] Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011;29:25–31.
[4] Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006;13:279–92.
[5] Cubulcu E, Olmez OF, Kanat O, et al. Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer. Contemp Oncol (Poln) 2014;18:34–8.
[6] Dalal CM, Brin顿 LA, Bauer DC, et al. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B-HeFT cohort. Endocr Relat Cancer 2013;20:151–60.
[7] Dossus L, Rinaldi S, Biessy C, et al. Circulating leptin and adiponectin, and breast density in premenopausal Mexican women: the Mexican Women’s Teachers’ Cohort. Cancer Causes Control 2017;28:939–46.
[8] Nagaraju GP, Rajitha B, Aliya S, et al. The role of adiponectin in obesity-associated female-specific carcinogenesis. Cytokine Growth Factor Rev 2016;31:37–48.
[9] Nalabolu MR, Palasamudram K, Jamil K. Adiponectin and leptin molecular actions and clinical significance in breast cancer. Int J Hematol Oncol Stem Cell Res 2014;8:31-40.
[10] Bachelard RE, Wendi MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203–6.
[11] Lyons A, Coleman M, Riss S, et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J Biol Chem 2017;292:16983–98.
[12] Georgiou GP, Provatopoulou X, Kalogeris E, et al. Serum resistin is inversely related to breast cancer risk in premenopausal women. Breast 2016;29:163–9.
[13] Hancke K, Grubbeck D, Hauser N, et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010;119:367–376.
[14] Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111:762–77.
[15] Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 2002;13:741–51.
[16] Assiri AM, Kamel HF, Hassanien MF. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal Saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers 2015;2015:253519.
[17] Ahmed SD, Khanam A, Sultan N, et al. Serum adiponectin level association with breast cancer risk: evidence from a case-control study. Asian Pac J Cancer Prev 2015;16:4945–8.
[18] Gui Y, Pan Q, Chen X, et al. The association between obesity related adipokines and risk of breast cancer: a meta-analysis. Oncotarget 2017;8:75389–99.
[19] Ye J, Jia J, Dong S, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev 2014;23:158–65.
[20] Macis D, Guarneri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol 2014;43:1226–36.
[21] Liu LY, Wang M, Ma ZB, et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS One 2013;8:e75183.
[22] Ollberding NJ, Kim Y, Shvetsov YB, et al. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res 2013;6:188–95.
[23] Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al. Adipokynes, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2013;22:1319–24.
[24] Li J, Han X. Adipokynes and breast cancer. Curr Probl Cancer 2018;42:208–14.
[25] Rose DP, Komminou D, Stephenson GD. Obesity, adipokynes, and insulin resistance in breast cancer. Obes Rev 2004;5:153–65.
[26] Silva FM, de Almeida JC, Feoli AM. Effect of diet on adipokine levels in blood. Nutr Rev 2011;69:599–612.
[27] Ozmen HK, Erdemci B, Askin S, et al. Carnitine and adipokine levels in breast cancer after radiotherapy. Open Med (Wars) 2017;12:189–94.
[28] Crisostomo J, Matafome P, Santos-Silva D, et al. Hyperresistinemia and metabolic dysregulation: a risky crosstalk in obese breast cancer. Endocrine 2016;53:433–42.
[29] Minato M, Kurotobi G, Asakura S, et al. Relationship of serum isoflavone, insulin and adipokine levels with breast cancer risk. Breast Cancer 2015;22:452–61.
[30] Guo MM, Duan XN, Cui SD, et al. Circulating high-molecular-weight (HMW) adipokine level is related with breast cancer risk better than total adipokine: a case-control study. PLoS One 2015;10:e0129246.
[31] Gunter MJ, Wang T, Cushman M, et al. Circulating adipokynes and inflammatory markers and postmenopausal breast cancer risk. J Natl Cancer Inst 2015;107:221–9.
[32] Wang Y, Zhang SQ. Correlation of serum adipokine, body mass index and lipid metabolic disorder and breast cancer. Chin J Lab Diagn 2013;17:210–7.
[33] Touvier M, Fezeu L, Ahluwalia N, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3–13.
[34] Santillan-Benitez JG, Mendieta-Zeron H, Gomez-Olivan LM, et al. The tetrad BMI, leptin, leptin/adipokine (L/A) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal 2013;27:12–20.
[35] Wang D, Xie T, Xu J, et al. Genetic association between NFKB1-94 ins/del ATTG promoter polymorphism and cancer risk: a meta-analysis of 42 case-control studies. Sci Rep 2016;6:30220.
[36] Tworoger SS, Eklason AH, Kelesidis T, et al. Plasma adipokine concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007;92:1510–6.
[37] Dalamaga M, Karmanolias K, Papadavid E, et al. Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 2013;20:845–51.
[38] Alokail MS, Al-Daghri N, Abdulkareem A, et al. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 2013;13:54.
[39] Zhang JX, Ma ZB, Yu LX, et al. Associations between breast cancer and serum levels of adipokine and leptin. J Shandong Univ 2012;50:132–8.
[40] Gucekli MA, Colakoglu K, Dincer H, et al. Associations between adipokynes and two different cancers: breast and colon. Asian Pac J Cancer Prev 2012;13:3955–8.
[41] Al Awadhi SA, Al Khalidi RM, Al Rammah T, et al. Associations of adipokynes & insulin resistance with sex steroids in patients with breast cancer. Indian J Med Res 2012;135:500–5.
[42] Al Khalidi RM, Al Mulla F, Al Awadhi S, et al. Associations of single nucleotide polymorphisms in the adipokine gene with adipokine levels and cardio-metabolic risk factors in patients with cancer. Dis Markers 2011;30:197–212.
[43] Shahar S, Salleh RM, Ghazali AR, et al. Roles of adiposity, lifetime physical activity and serum adipokine in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev 2010;11:61–6.
[44] Fan J, Liu B, WG G. Postoperative radiotherapy combined with temozolomide treatment of malignant gliomas. J Pract Oncol 2010;23:192–7.
[45] Cust AE, Stocks T, Lukanova A, et al. The influence of overweight and obesity on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009;113:567–76.
[46] Korner A, Pazzaitou-Panayiotou K, Kelesidis T, et al. Total and high-molecular-weight adipokine in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041–8.
[47] Kang JH, Yu BY, Youn DS. Relationship of serum adipokine and resistin levels with breast cancer risk. J Korean Med Sci 2007;22:117–21.
[48] Hou WK, Xu YX, Yu T, et al. Adipokynes in breast cancer risk. Chin Med J (Engl) 2007;120:1392–6.
[49] Chen DC, Chung YF, Yeh YT, et al. Serum adipokine and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109–14.
[50] Mantzoros C, Petridou E, Dessypris N, et al. Adipokine in breast cancer risk. J Clin Endocrinol Metab 2004;89:1102–7.
[51] Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adipokine levels with breast cancer risk. Clin Cancer Res 2003;9:5699–704.
[52] Panis C, Herrera AC, Aranome AM, et al. Clinical insights from adipokine analysis in breast cancer patients reveal its anti-inflammatory properties in non-obese women. Mol Cell Endocrinol 2014;382:190–6.
[53] Llamos AA, Brasky TM, Mathew J, et al. Genetic variation in adipokine genes and associations with adipokine and leptin concentrations in plasma and breast tissue. Cancer Epidemiol Biomarkers Prev 2014;23:1559–68.
[54] Cho YA, Sung MK, Yeon JY, et al. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res Treat 2013;45:210–9.
[55] Carroll PA, Healy L, Lysaght J, et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mol Carcinog 2011;50:643–51.
[56] Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011;10:13.
[57] Palm MF, Bordignon VV, Murphy BD. Adipokine and the control of female reproductive functions. Vitam Horm 2012;90:239–87.
[58] Maruthur NM, Bolen SD, Brancafi FL, et al. The association of obesity and cervical cancer screening: a systematic review and meta-analysis. Obstet Gynecol Surv 2009;74:373–81.
[59] Cust AE, Kaaks R, Friedenreich C, et al. Plasma adipokine levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007;92:253–63.
[60] Kishida K, Funahashi T, Shimomura I. Adipokine as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014;28:119–30.